Last reviewed · How we verify
SCT-I10A+chemo
SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents.
SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents. Used for Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer.
At a glance
| Generic name | SCT-I10A+chemo |
|---|---|
| Also known as | SCT-I10A |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SCT-I10A is designed to modulate the immune system to recognize and attack cancer cells more effectively. When combined with chemotherapy, it aims to both reduce tumor size and prevent recurrence by leveraging the synergistic effects of both treatments.
Approved indications
- Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer
Common side effects
- Neutropenia
- Fatigue
- Nausea
Key clinical trials
- SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PHASE1)
- SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (PHASE3)
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC (PHASE1)
- Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT-I10A+chemo CI brief — competitive landscape report
- SCT-I10A+chemo updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI